- France coach Deschamps to step down after 2026 World Cup
- French magazine run by autistic journalists hits newsstands
- US, Canadian and Australian travellers now face UK entry fee
- France urges European Commission to be firm against Musk interference
- Wildfire sparks panicked evacuations in Los Angeles suburbs
- Nobel winner Ressa tells AFP 'dangerous times' ahead after Meta ends US fact-checking
- Indonesia upholds iPhone 16 sales ban after Apple offers $1 bn investment
- Dutch great Kluivert named Indonesia coach in hunt for World Cup spot
- UK's Catherine turns 43 hoping for better year
- France coach Deschamps says will leave after 2026 World Cup
- South Syria fighters reluctant to give up weapons: spokesman
- Dutch great Kluivert named coach of Indonesia
- New Zealand crush Sri Lanka by 113 runs in 2nd ODI to win series
- West Ham cancel Lopetegui press conference as sacking rumours swirl
- Questions remain over South African involvement in Champions Cup
- OpenAI chief Sam Altman denies sister's sexual abuse accusations
- Hundreds rally for South Korea's Yoon as new arrest bid beckons
- Bangladesh orders banks to assist UK minister graft probe
- Germans turn to balcony solar panels to save money
- Theekshana hat-trick restricts NZ to 255-9 in 2nd Sri Lanka ODI
- Young's buzzer-beater lifts Hawks, Celtics down Nuggets
- Grief and nostalgia in India's 'Jimmy Carter village'
- Venezuela's 'colectivos' ready to pounce as opposition plans protest
- Thai police hunt suspect over Cambodian politician shooting
- Venezuela on tenterhooks ahead of rival protests, Maduro swearing-in
- Devajit Saikia: lawyer, modest player and next India cricket chief
- S. Korea's impeached President Yoon holds out in capital 'fortress'
- Samsung warns fourth-quarter profit to miss forecasts
- China's viral wild boar hunters attract fame and concern
- Forgotten but not gone: Covid keeps killing, five years on
- Is the world ready for the next pandemic?
- Trump's provocative, often confusing, US foreign policy is back
- Rescuers search for survivors after quake in China's Tibet kills at least 126
- Brazil gears up for first climate conference in Amazon
- In Brazil, an Amazon reforestation project seeks to redeem carbon markets
- Djokovic with point to prove against younger rivals at Australian Open
- Asian markets mixed after Wall St hit by US inflation fears
- Mexicans offered $1,300 to hand in a machine gun
- Venezuela arrests two Americans, five other 'mercenaries'
- Iraqi archaeologists piece together ancient treasures ravaged by IS
- Big Tech rolls out the red carpet for Trump
- Kyrgios suffers new injury setback days before Australian Open
- Former US president Carter lies in state after somber Washington procession
- US company Firefly Aerospace to launch for Moon next week
- Don't eat your Christmas tree, warns Belgium food agency
- No proof fentanyl produced in Mexico, president says
- Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000
- Guardian Metal Resources PLC Announces Garfield - High-Grade Antimony-Gold Assay
- Mosquitoes with 'toxic' semen could stem disease spread: research
RBGPF | 100% | 59.31 | $ | |
RYCEF | -0.42% | 7.17 | $ | |
NGG | -0.46% | 58.6 | $ | |
CMSC | -1.12% | 23.23 | $ | |
BP | 2.54% | 31.83 | $ | |
SCS | -2.14% | 11.2 | $ | |
RELX | 0.72% | 45.98 | $ | |
BTI | -0.52% | 36.78 | $ | |
RIO | -0.33% | 58.19 | $ | |
GSK | 0.38% | 34.09 | $ | |
VOD | -0.71% | 8.41 | $ | |
JRI | -1.88% | 12.22 | $ | |
BCC | -1.69% | 118.22 | $ | |
BCE | -0.34% | 23.86 | $ | |
CMSD | -1.15% | 23.46 | $ | |
AZN | -0.3% | 66.64 | $ |
US judges appear skeptical of preserving access to abortion pill
A US federal appeals court panel appeared skeptical on Wednesday of preserving access to a widely used abortion pill.
The three conservative judges pushed back against government arguments that the decision on whether to allow the use of mifepristone should be left to the Food and Drug Administration (FDA), which approved the drug more than 20 years ago.
"We are allowed to look at the FDA just like we're allowed to look at any agency," said Judge James Ho. "That's the role of the courts."
Anti-abortion groups are seeking to have mifepristone banned, claiming despite its long track record that it is unsafe. The case is the latest skirmish in the battle over reproductive rights in the United States.
Ho and one of the other judges on the panel of the New Orleans-based 5th Circuit Court of Appeals were appointed by former president Donald Trump, while the third was also named by a Republican president, George W. Bush.
All three judges seemed unconvinced by arguments by the Justice Department of Democratic President Joe Biden and lawyers for mifepristone manufacturer Danco that the drug should be allowed to remain on the market.
The case stems from a ruling by a conservative US District Court judge in Texas that would have banned mifepristone, which accounts for more than half of the abortions in the United States.
The 5th Circuit Court blocked a ban on the abortion pill, but imposed tough restrictions on access, after which the baton was handed to the Supreme Court, where conservatives wield a 6-3 majority.
The Supreme Court temporarily preserved access to mifepristone, freezing the rulings by the lower courts, and sent the case back to the 5th Circuit.
Jennifer Dalven, director of the ACLU Reproductive Freedom Project, was pessimistic following Wednesday's hearing.
"The arguments today demonstrated in detail that the case has no legal or scientific merit and should have been laughed out of court from the very start," Dalven said.
"Unfortunately, the deck is stacked as the judges hearing this case are well known for their extraordinary hostility to abortion," Dalven said.
Any ruling by the appellate court is likely to eventually reach the Supreme Court, which overturned the constitutional right to abortion 11 months ago.
Since then, more than a dozen states have banned abortion and it has been severely restricted in others.
Mifepristone is one component of a two-drug regimen that can be used through the first 10 weeks of pregnancy.
It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved in 2000.
B.Finley--AMWN